

# David J Kuter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6154527/publications.pdf>

Version: 2024-02-01

166  
papers

9,714  
citations

57631

44  
h-index

38300

95  
g-index

190  
all docs

190  
docs citations

190  
times ranked

7761  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020, 136, 489-500.	0.6	1,021
2	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet</i> , The, 2008, 371, 395-403.	6.3	784
3	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	2.5	684
4	Thrombocytopenia caused by the development of antibodies to thrombopoietin. <i>Blood</i> , 2001, 98, 3241-3248.	0.6	658
5	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3780-3817.	2.5	593
6	Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2010, 363, 1889-1899.	13.9	374
7	Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. <i>Blood</i> , 2002, 100, 3457-3469.	0.6	351
8	New thrombopoietic growth factors. <i>Blood</i> , 2007, 109, 4607-4616.	0.6	312
9	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. <i>Blood Reviews</i> , 2020, 41, 100648.	2.8	267
10	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. <i>British Journal of Haematology</i> , 2007, 139, 351-362.	1.2	249
11	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. <i>British Journal of Haematology</i> , 2013, 161, 411-423.	1.2	234
12	Thrombotic Complications of Central Venous Catheters in Cancer Patients. <i>Oncologist</i> , 2004, 9, 207-216.	1.9	213
13	The biology of thrombopoietin and thrombopoietin receptor agonists. <i>International Journal of Hematology</i> , 2013, 98, 10-23.	0.7	197
14	Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. <i>Blood</i> , 2009, 114, 3748-3756.	0.6	177
15	Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia. <i>Annual Review of Medicine</i> , 2009, 60, 193-206.	5.0	164
16	The mechanism of apoptosis in human platelets during storage. <i>Transfusion</i> , 2000, 40, 1320-1329.	0.8	156
17	Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. <i>British Journal of Haematology</i> , 1999, 106, 345-356.	1.2	147
18	Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. <i>Haematologica</i> , 2018, 103, 1433-1443.	1.7	123

#	ARTICLE	IF	CITATIONS
19	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014, 123, 3887-3894.	0.6	112
20	The Physiology of Platelet Production. <i>Stem Cells</i> , 1996, 14, 88-101.	1.4	111
21	Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. <i>American Journal of Hematology</i> , 2020, 95, 178-187.	2.0	99
22	New Thrombopoietic Growth Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S347-S356.	1.4	95
23	Biology and Chemistry of Thrombopoietic Agents. <i>Seminars in Hematology</i> , 2010, 47, 243-248.	1.8	93
24	Thrombopoietin therapy increases platelet yields in healthy platelet donors. <i>Blood</i> , 2001, 98, 1339-1345.	0.6	89
25	Milestones in understanding platelet production: a historical overview. <i>British Journal of Haematology</i> , 2014, 165, 248-258.	1.2	85
26	Exacerbation of immune thrombocytopenia following COVID-19 vaccination. <i>British Journal of Haematology</i> , 2021, 195, 365-370.	1.2	72
27	Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists. <i>American Journal of Hematology</i> , 2013, 88, 1041-1044.	2.0	70
28	Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. <i>American Journal of Hematology</i> , 2012, 87, 558-561.	2.0	68
29	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984173.	1.1	65
30	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. <i>Haematologica</i> , 2021, 106, 2161-2169.	1.7	64
31	Thrombopoietin and Platelet Production in Chronic Immune Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1193-1211.	0.9	60
32	Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 116-124.	0.6	60
33	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 9-18.	2.5	56
34	Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. <i>American Journal of Hematology</i> , 2018, 93, 1501-1508.	2.0	55
35	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2019, 94, 149-161.	2.0	55
36	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	0.6	55

#	ARTICLE	IF	CITATIONS
37	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2022, 386, 1421-1431.	13.9	52
38	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 122-129.	0.5	51
39	The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. <i>Haematologica</i> , 2018, 103, e169-e172.	1.7	51
40	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. <i>International Journal of Hematology</i> , 2015, 101, 255-263.	0.7	49
41	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017, 92, 730-738.	2.0	49
42	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<sc>ITP</sc>) for up to 1 year and in those with chronic <sc>ITP</sc> for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. <i>British Journal of Haematology</i> , 2019, 185, 503-513.	1.2	49
43	Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 275-288.	1.5	49
44	A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. <i>Haematologica</i> , 2021, 106, 1148-1157.	1.7	49
45	Cancer, Coagulation, and Anticoagulation. <i>Oncologist</i> , 1999, 4, 443-449.	1.9	48
46	The End Is Just the Beginning: Megakaryocyte Apoptosis and Platelet Release. <i>International Journal of Hematology</i> , 2001, 74, 365-374.	0.7	45
47	Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. <i>Liver International</i> , 2022, 42, 161-172.	1.9	41
48	Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED) Delphi initiative. <i>Internal Medicine Journal</i> , 2019, 49, 578-591.	0.5	39
49	New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2008, 80, 9-18.	1.1	38
50	Hepatocellular carcinoma in Gaucher disease: an international case series. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 819-827.	1.7	37
51	Romiplostim for the management of perioperative thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 182, 106-113.	1.2	37
52	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 336-336.	0.6	36
53	Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. <i>Annals of Hematology</i> , 2019, 98, 581-588.	0.8	34
54	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. <i>Journal of Clinical Apheresis</i> , 1998, 13, 114-119.	0.7	31

#	ARTICLE	IF	CITATIONS
55	Thrombopoietin: Biology and Clinical Applications. <i>Oncologist</i> , 1996, 1, 98-106.	1.9	29
56	Romiplostim. <i>Cancer Treatment and Research</i> , 2010, 157, 267-288.	0.2	28
57	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2000, 111, 943-953.	1.2	27
58	Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 183, 168-168.	1.2	26
59	Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. <i>American Journal of Hematology</i> , 2020, 95, 1180-1186.	2.0	26
60	Romiplostim in the management of the thrombocytopenic surgical patient. <i>Transfusion</i> , 2015, 55, 2505-2510.	0.8	24
61	An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2673-2677.	1.1	24
62	Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. <i>Blood Advances</i> , 2019, 3, 3515-3521.	2.5	24
63	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (<scp>COVID</scp></sc>â€¹9). <i>American Journal of Hematology</i> , 2020, 95, 1479-1485.	2.0	24
64	Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia.. <i>Blood</i> , 2004, 104, 1775-1775.	0.6	23
65	Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-ascending, placebo-controlled Phase 1 studies. <i>British Journal of Haematology</i> , 2018, 183, 466-478.	1.2	22
66	Apoptosis in Platelets During Ex Vivo Storage. <i>Vox Sanguinis</i> , 2002, 83, 311-313.	0.7	21
67	Remissions after long-term use of romiplostim for immune thrombocytopenia. <i>Haematologica</i> , 2016, 101, e476-e478.	1.7	21
68	The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. <i>Blood Reviews</i> , 2022, 53, 100909.	2.8	21
69	The use of PEG&hyphen;rHuMGDF in platelet apheresis. <i>Stem Cells</i> , 1998, 16, 231-242.	1.4	19
70	The role of romiplostim for pediatric patients with immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091299.	1.1	19
71	An evaluation of avatrombopag for the treatment of thrombocytopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 273-280.	0.9	19
72	Novel therapies for immune thrombocytopenia. <i>British Journal of Haematology</i> , 2022, 196, 1311-1328.	1.2	19

#	ARTICLE	IF	CITATIONS
73	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. <i>American Journal of Hematology</i> , 2022, 97, 691-699.	2.0	19
74	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura. <i>Blood</i> , 2006, 108, 3982-3982.	0.6	18
75	Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. <i>Haematologica</i> , 2022, 107, 1698-1702.	1.7	18
76	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 579-584.e1.	0.2	16
77	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020, 98, 106459.	0.4	16
78	How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. <i>Blood</i> , 2021, 137, 2736-2744.	0.6	15
79	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. <i>Blood</i> , 2010, 116, 68-68.	0.6	15
80	Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. <i>American Journal of Hematology</i> , 2020, 95, 643-651.	2.0	14
81	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 219-225.	0.2	13
82	Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2020, 136, 14-15.	0.6	13
83	Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. <i>British Journal of Haematology</i> , 2020, 190, 923-932.	1.2	12
84	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. <i>Blood</i> , 2019, 134, 87-87.	0.6	12
85	TPO concentrations and response to romiplostim. <i>American Journal of Hematology</i> , 2014, 89, 1155-1156.	2.0	11
86	What is the potential for thrombopoietic agents in acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 553-558.	0.7	10
87	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020, 13, 1319-1332.	1.0	10
88	Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. <i>Blood</i> , 2008, 112, 402-402.	0.6	10
89	Recurrence of Acute Intermittent Porphyria After Liver Transplantation. <i>Annals of Internal Medicine</i> , 2019, 170, 904.	2.0	9
90	Scoring system to facilitate diagnosis of Gaucher disease. <i>Internal Medicine Journal</i> , 2020, 50, 1538-1546.	0.5	9

#	ARTICLE	IF	CITATIONS
91	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. <i>Blood Reviews</i> , 2021, 49, 100811.	2.8	9
92	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. <i>Blood</i> , 2019, 134, LBA-2-LBA-2.	0.6	9
93	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma. <i>Medicine (United States)</i> , 2018, 97, e13321.	0.4	8
94	A Randomized, Double-Blind, Placebo-Controlled Phase II Trial on the Efficacy, Safety and Tolerability of E5501 (AKR501) In Subjects with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2010, 116, 71-71.	0.6	8
95	Safety and Efficacy of PRTX-100, a Highly Purified Form of Staphylococcal Protein A, in Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016, 128, 4929-4929.	0.6	7
96	Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. <i>Haematologica</i> , 2018, 103, e492-e495.	1.7	6
97	Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. <i>British Journal of Haematology</i> , 2019, 187, e61-e64.	1.2	6
98	General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors. , 2019, , 108-126.		6
99	Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, 1563-1568.	2.0	6
100	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. <i>Blood</i> , 2018, 132, 3612-3612.	0.6	6
101	Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies. <i>Blood</i> , 2019, 134, 898-898.	0.6	6
102	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	0.6	6
103	Oral Riltabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia. <i>Blood</i> , 2020, 136, 13-14.	0.6	6
104	What is the role of novel thrombopoietic agents in the management of acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 372-378.	0.7	5
105	Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features. <i>Blood</i> , 2018, 132, 1137-1137.	0.6	5
106	Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2010, 116, 3701-3701.	0.6	5
107	An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy. <i>Blood</i> , 2016, 128, 2403-2403.	0.6	5
108	Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Riltabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 14-14.	0.6	5



#	ARTICLE	IF	CITATIONS
109	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 1010-1010.	0.6	5
110	Pure White Cell Aplasia and Necrotizing Myositis. <i>Case Reports in Hematology</i> , 2016, 2016, 1-5.	0.3	4
111	Case 38-2020: A 52-Year-Old Man with Cancer and Acute Hypoxemia. <i>New England Journal of Medicine</i> , 2020, 383, 2372-2383.	13.9	4
112	Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 82, 102418.	0.6	4
113	Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>American Journal of Hematology</i> , 2021, 96, E235-E237.	2.0	4
114	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. <i>Blood</i> , 2020, 136, 13-13.	0.6	4
115	Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study. <i>Blood</i> , 2020, 136, 1-3.	0.6	4
116	Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.. <i>Blood</i> , 2009, 114, 679-679.	0.6	4
117	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. <i>Blood</i> , 2009, 114, 681-681.	0.6	4
118	Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2010, 116, 3695-3695.	0.6	4
119	Thrombopoietin Levels May Predict Responsiveness to Therapy with Thrombopoietin Agonists Among Patients with Immune Thrombocytopenic Purpura,. <i>Blood</i> , 2011, 118, 3288-3288.	0.6	4
120	In Reply: Low-dose Warfarin Prophylaxis for Catheter-associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5-Fluorouracil-based Chemotherapy?. <i>Oncologist</i> , 2004, 9, 596-596.	1.9	3
121	Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00118.	1.3	3
122	Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. , 1998, 13, 114.		3
123	Assessment of Romiplostim Immunogenicity in Adult Patients in Clinical Trials and in a Global Registry. <i>Blood</i> , 2018, 132, 2427-2427.	0.6	3
124	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. <i>Blood</i> , 2019, 134, 3518-3518.	0.6	3
125	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). <i>Blood</i> , 2021, 138, 2088-2088.	0.6	3
126	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. <i>Blood</i> , 2020, 136, 24-25.	0.6	3



#	ARTICLE	IF	CITATIONS
127	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplantation, 2020, 55, 1178-1180.	1.3	2
128	Preparing patients with immune thrombocytopenia for surgery: what are the options?. Lancet Haematology, 2020, 7, e626-e627.	2.2	2
129	Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report. BMC Pregnancy and Childbirth, 2020, 20, 365.	0.9	2
130	Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2021, 110, 1570-1578.	2.3	2
131	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia.. Blood, 2006, 108, 1049-1049.	0.6	2
132	A Comparative Proteomic Analysis of Platelets from Healthy Human Patients and Chronic ITP Patients Receiving AMG 531, a Thrombopoiesis-Stimulating Protein.. Blood, 2007, 110, 1313-1313.	0.6	2
133	Romiplostim for Treatment and Prevention of Chemotherapy-Associated Thrombocytopenia. Blood, 2016, 128, 3748-3748.	0.6	2
134	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database. Blood, 2018, 132, 3284-3284.	0.6	1
135	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. Blood, 2018, 132, 3740-3740.	0.6	1
136	Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia. Blood, 2019, 134, 895-895.	0.6	1
137	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. Blood, 2006, 108, 4097-4097.	0.6	1
138	Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC). Blood, 2010, 116, 569-569.	0.6	1
139	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. Blood, 2015, 126, 2093-2093.	0.6	1
140	Markers of Autoimmunity in Immune Thrombocytopenia: Prevalence and Prognostic Significance. Blood, 2016, 128, 1363-1363.	0.6	1
141	Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative. Blood, 2016, 128, 4886-4886.	0.6	1
142	Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.. Journal of Clinical Oncology, 2016, 34, 6621-6621.	0.8	1
143	Thrombopoietin Level Predicts Response to Treatment with Eltrombopag and Romiplostim in Immune Thrombocytopenia. Blood, 2018, 132, 734-734.	0.6	1
144	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood, 2021, 138, 586-586.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 325-330.	0.7	0
146	Long-Term Follow-Up of Monoclonal Gammopathies in Gaucher Disease Patients on Enzyme Replacement Therapy. <i>Blood</i> , 2006, 108, 3336-3336.	0.6	0
147	Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis. <i>Blood</i> , 2008, 112, 5251-5251.	0.6	0
148	The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year. <i>Blood</i> , 2010, 116, 3702-3702.	0.6	0
149	Thrombin Generation During Abdominal Surgical Procedures: Effect of Prophylactic Anticoagulation Therapy. <i>Blood</i> , 2010, 116, 3183-3183.	0.6	0
150	Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate. <i>Blood</i> , 2011, 118, 2220-2220.	0.6	0
151	Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study. <i>Blood</i> , 2011, 118, 3207-3207.	0.6	0
152	A Double-Blind, Placebo-Controlled, and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ono-7746 in Healthy Subjects. <i>Blood</i> , 2011, 118, 4828-4828.	0.6	0
153	Single Oral Doses of a Novel Thrombopoietin Mimetic ONO-7746 Increase Platelet Counts In Healthy Subjects. <i>Blood</i> , 2011, 118, 4827-4827.	0.6	0
154	Romiplostim in Management of the Thrombocytopenic Surgical Patient. <i>Blood</i> , 2014, 124, 1459-1459.	0.6	0
155	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Key Presenting Signs and Patient Co-Variables in Type 1 Disease. <i>Blood</i> , 2016, 128, 3676-3676.	0.6	0
156	A Global Delphi Consensus Initiative for Early Diagnosis of Gaucher Disease: Barriers, Their Resolution and the Impact on Patients. <i>Blood</i> , 2016, 128, 4885-4885.	0.6	0
157	FF-10102-01: A Novel, Highly Selective Spleen Tyrosine Kinase Inhibitor, to Be in Clinical Application for Treatment of Autoimmune Diseases and B-Cell Malignancies. <i>Blood</i> , 2016, 128, 3745-3745.	0.6	0
158	Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. <i>Blood</i> , 2018, 132, 3285-3285.	0.6	0
159	Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy. <i>Blood</i> , 2018, 132, 3755-3755.	0.6	0
160	Systemic Bevacizumab for the Treatment of Chronic Bleeding in Hereditary Hemorrhagic Telangiectasia. <i>Blood</i> , 2018, 132, 852-852.	0.6	0
161	An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study. <i>Blood</i> , 2019, 134, 1060-1060.	0.6	0
162	Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia. <i>Blood</i> , 2019, 134, 4800-4800.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia. <i>Blood</i> , 2021, 138, 584-584.	0.6	0
164	Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
165	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. <i>Blood</i> , 2020, 136, 29-29.	0.6	0
166	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020, 136, 4-5.	0.6	0